Journal Article Review Epublish
PubMed: 40589542 DOI: 10.1155/ijh/5580454
Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies.
Int J Hepatol 2025:5580454
Authors: John Cooper, Parth Patel, Joven Tristeza, Alexander Yang
Affiliations
- Internal Medicine, University of Alabama, Birmingham, Alabama, USA.
Abstract
Metabolic-associated steatotic liver disease (MASLD) is a burgeoning worldwide burden and is currently the leading indication for a liver transplant. Despite the growing burden of disease, there are few pharmacological treatments available. The underlying molecular mechanisms of the development of MASLD are still being elucidated. In this review, we will summarize the known molecular mechanisms in the development of MASLD along with past, current, and future pharmacologic clinical trials.
MeSH
Liver Diseases, Liver, Therapeutics